Crinetics Pharmaceuticals (CRNX) Short Interest Ratio & Short Volume → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free CRNX Stock Alerts $47.20 +0.42 (+0.90%) (As of 05/3/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Crinetics Pharmaceuticals Short Interest DataCurrent Short Volume5,220,000 sharesPrevious Short Volume4,910,000 sharesChange Vs. Previous Month+6.31%Dollar Volume Sold Short$228.01 millionShort Interest Ratio / Days to Cover6.5Last Record DateApril 15, 2024Outstanding Shares78,740,000 sharesPercentage of Shares Shorted6.63%Today's Trading Volume679,390 sharesAverage Trading Volume630,942 sharesToday's Volume Vs. Average108% Short Selling Crinetics Pharmaceuticals ? Sign up to receive the latest short interest report for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCRNX Short Interest Over TimeCRNX Days to Cover Over TimeCRNX Percentage of Float Shorted Over Time Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. Crinetics Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20245,220,000 shares $228.01 million +6.3%N/A6.5 $43.68 3/31/20244,910,000 shares $229.84 million -2.0%N/A6.1 $46.81 3/15/20245,010,000 shares $195.04 million +5.7%N/A6.7 $38.93 2/29/20244,740,000 shares $194.06 million +5.1%N/A6 $40.94 2/15/20244,510,000 shares $166.51 million -11.1%N/A5.8 $36.92 1/31/20245,070,000 shares $184.95 million -0.8%N/A6.2 $36.48 Get the Latest News and Ratings for CRNX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20245,110,000 shares $190.04 million -0.6%N/A6 $37.19 12/31/20235,140,000 shares $182.88 million -13.6%N/A5.9 $35.58 12/15/20235,950,000 shares $205.04 million -6.7%N/A6.4 $34.46 11/30/20236,380,000 shares $202.82 million +2.9%N/A4 $31.79 11/15/20236,200,000 shares $179.06 million -7.6%N/A4 $28.88 10/31/20236,710,000 shares $196.54 million -1.5%N/A4.4 $29.29 10/15/20236,810,000 shares $198.24 million +16.4%N/A4.7 $29.11 9/30/20235,850,000 shares $173.98 million +43.7%N/A4.1 $29.74 9/15/20234,070,000 shares $120.02 million -10.4%N/A3.1 $29.49 8/31/20234,540,000 shares $78.63 million +21.4%N/A5.2 $17.32 8/15/20233,740,000 shares $62.53 million +11.0%N/A7.9 $16.72 7/31/20233,370,000 shares $64.03 million -2.9%N/A7.2 $19.00 7/15/20233,470,000 shares $70.68 million +1.5%N/A7.2 $20.37 6/30/20233,420,000 shares $61.63 million +4.0%N/A7.6 $18.02 6/15/20233,290,000 shares $68.33 million No ChangeN/A7 $20.77 5/31/20233,290,000 shares $71.82 million -4.4%N/A7.2 $21.83 5/15/20233,440,000 shares $76.82 million -18.9%N/A7.7 $22.33 4/30/20234,240,000 shares $82.85 million -1.2%N/A9.9 $19.54 4/15/20234,290,000 shares $68.34 million -6.3%N/A10.6 $15.93 3/31/20234,580,000 shares $73.55 million +12.3%N/A10.8 $16.06 3/15/20234,080,000 shares $70.14 million +12.1%N/A10.1 $17.19 2/28/20233,640,000 shares $71.49 million +7.4%N/A8.9 $19.64 2/15/20233,390,000 shares $67.70 million -4.0%N/A8.8 $19.97 1/31/20233,530,000 shares $69.22 million -5.4%N/A9.3 $19.61 1/15/20233,730,000 shares $67.29 million No ChangeN/A11.1 $18.04 12/30/20223,730,000 shares $68.26 million +3.3%N/A11.7 $18.30 12/15/20223,610,000 shares $58.63 million -5.3%N/A12.1 $16.24 11/30/20223,810,000 shares $68.08 million -1.3%N/A14.3 $17.87 11/15/20223,860,000 shares $70.41 million -3.7%N/A14.3 $18.24 10/31/20224,010,000 shares $74.02 million -1.7%N/A14.4 $18.46 10/15/20224,080,000 shares $72.05 million +1.5%N/A15 $17.66 9/30/20224,020,000 shares $78.95 million +3.1%N/A15.6 $19.64 9/15/20223,900,000 shares $83.34 million +9.9%N/A14 $21.37 8/31/20223,550,000 shares $67.02 million +13.4%N/A12.3 $18.88Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. CRNX Short Interest - Frequently Asked Questions What is Crinetics Pharmaceuticals' current short interest? Short interest is the volume of Crinetics Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 5,220,000 shares of CRNX short. Learn More on Crinetics Pharmaceuticals' current short interest. What is a good short interest ratio for Crinetics Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRNX shares currently have a short interest ratio of 6.0. Learn More on Crinetics Pharmaceuticals's short interest ratio. Which institutional investors are shorting Crinetics Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Crinetics Pharmaceuticals: Concourse Financial Group Securities Inc., Simplex Trading LLC, Nomura Holdings Inc., and Affinity Asset Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Crinetics Pharmaceuticals' short interest increasing or decreasing? Crinetics Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 5,220,000 shares, an increase of 6.3% from the previous total of 4,910,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Crinetics Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Crinetics Pharmaceuticals: Biohaven Ltd. (10.10%), Ultragenyx Pharmaceutical Inc. (5.27%), Prestige Consumer Healthcare Inc. (3.72%), Insmed Incorporated (6.33%), HUTCHMED (China) Limited (0.30%), Bausch Health Companies Inc. (5.81%), CymaBay Therapeutics, Inc. (5.10%), Xenon Pharmaceuticals Inc. (3.47%), IDEAYA Biosciences, Inc. (14.86%), Amicus Therapeutics, Inc. (10.57%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Crinetics Pharmaceuticals stock? Short selling CRNX is an investing strategy that aims to generate trading profit from Crinetics Pharmaceuticals as its price is falling. CRNX shares are trading up $0.42 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Crinetics Pharmaceuticals? A short squeeze for Crinetics Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CRNX, which in turn drives the price of the stock up even further. How often is Crinetics Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRNX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Biohaven Short Interest Data Ultragenyx Pharmaceutical Short Interest Data Prestige Consumer Healthcare Short Interest Data Insmed Short Interest Data HUTCHMED Short Interest Data Bausch Health Companies Short Interest Data CymaBay Therapeutics Short Interest Data Xenon Pharmaceuticals Short Interest Data IDEAYA Biosciences Short Interest Data Amicus Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CRNX) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith